

Supporting Information

Two-dimensional high performance liquid chromatography purification of underivatized urinary prednisone and prednisolone for compound-specific stable carbon isotope analysis

Zhongquan Li^a and Bing Liu^{*a}


^a Research Institute for Doping Control, Shanghai University of Sport, 900 Jiangwancheng Road, Shanghai 200438, China

*Corresponding author: liubing2019@sus.edu.cn


1. Table S1 Compounds in CUPCC

Compounds	$\delta^{13}\text{C}$ (‰)
Etio	-28.75±0.01
A	-26.74±0.03
PD	-18.65±0.03

2. Fig. S1 Schematics of the 2D-HPLC instrumentation without trap mode.




3. Fig. S2 Results of the 2D-HPLC instrumentation without trap mode. (A: 2D-HPLC Chromatograms for PS and PSL; B Pressure line of 2D-HPLC; C: GC chromatograms for PSL.)




4. Table S2: The $\delta^{13}\text{C}$ comparison between before and after purification for PS and PSL.

Compound	Before-Purification ($n=6$) $\delta^{13}\text{C}$ (‰)	Post-Purification ($n=6$) $\delta^{13}\text{C}$ (‰)	Difference (‰)
PS	-30.27 ± 0.29	-30.34 ± 0.36	0.07
PSL	-30.41 ± 0.30	-30.62 ± 0.25	0.21

5. Fig. S3 HPLC overlap chromatograms after ten injections of standard solutions. (A: 1D-HPLC chromatograms of MT; B: 2D-HPLC chromatograms of Dex)



6. Fig. S4 HPLC chromatograms after ten injections of urine samples. (A: 1D-HPLC chromatograms; B: 2D-HPLC chromatograms)



7. Fig. S5: Mass spectrum obtained from GC/MS. (A: Mass spectrum of PS; B: Mass spectrum of PSL)

